News | Breast Imaging | January 17, 2017

Additional Data Validates Potential of Imagio Opto-Acoustic Breast Imaging System to Reduce Negative Biopsies

New Data Presented at San Antonio Breast Cancer Symposium Confirms Correlation Between the Imagio Opto-Acoustic Breast Imaging System and Histologic Grade of Breast Masses

Seno Medical Instruments, Inc. announced results from two analyses of the company's European MAESTRO post-market surveillance study. The two analyses were presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in San Antonio.

MAESTRO, a controlled, multi-center, observational, post-market surveillance and clinical follow-up study, was designed to assess the diagnostic value (specificity and sensitivity) of OA to conventional diagnostic ultrasound (CDU) in suspicious masses classified as BI-RADS 4a and 4b. Investigators first performed CDU to reach a diagnosis and decision to biopsy followed by an Imagio OA examination. Two hundred female subjects with undiagnosed suspicious masses enrolled in the study.

The first analysis evaluated the correlation between OA imaging results and histologic data of breast masses and found that there was a statistically significant correlation between the OA breast imaging results and those based on histopathologic analysis.

"These studies are an important step forward in the development of noninvasive breast imaging technology. Evaluation of the Imagio system significantly included an independent analysis of the patient's pathology, unparalleled in the pre-release development of any breast imaging technology," said F. Lee Tucker, MD, FCAP and pathologist for the PIONEER study in the U.S. "The findings indicate the Imagio system can provide an accurate and noninvasive differentiation of benign from cancerous breast masses and will be an important means of reducing the number of benign breast biopsies."

The histopathological examination revealed 146 benign masses and 67 malignant masses. For each mass, five pre-determined OA features, three internal features, and two external features were evaluated. The three internal scores (vessels, blush, and hemoglobin) and two external features (capsular boundary zone and peripheral boundary zone) were summed together and separately for testing relationships utilizing traditional histopathology measures. The OA feature scores statistically significantly differentiate between benign and malignant masses and appear to correlate to histologic grade.

The second study, an interim analysis from the MAESTRO study, presented OA imaging downclassification and upclassifciation data, which showed that the Imagio system improved physicians' ability to accurately classify breast masses as malignant or benign compared to using traditional ultrasound. Results from this study were first presented at the Annual Scientific Meeting of the European Society of Breast Imaging (EUSOBI), the second largest conference in the world dedicated to breast cancer imaging, in September 2016 in Paris.

"The interim results from the MAESTRO study provide further evidence in a real-world setting, that the Imagio breast imaging system is a viable diagnostic tool to more accurately assess breast masses for malignancy compared to diagnostic ultrasound," said Ruud Pijnappel M.D., Ph.D., Professor Breast Radiology at UMC Utrecht, Netherlands and CEO of LRBC - Dutch Reference Centre for Screening. "We believe the final results of the MAESTRO study to be presented in 2017 will confirm these interim results."

"Together, the two data presentations presented at the San Antonio Breast Cancer Symposium reinforce our belief that the Imagio breast imaging system will be an important tool to clinicians to evaluate suspicious masses while providing greater comfort to the patient," said Tom Umbel, CEO of Seno Medical Instruments. "We will soon launch the Imagio system in Europe and look forward to the presenting the MAESTRO final results and the results of our pivotal trial in the US – PIONEER – in 2017."

Seno Medical Instruments expects to announce the final results from the MAESTRO study in early 2017. Results from the company's PIONEER study in the U.S. of more than 2,000 patients are expected to be announced in the second half of 2017. Seno Medical is targeting their PMA submission for the Imagio system to the U.S Food and Drug Administration in early 2017.

Seno's Imagio system co-registers and fuses opto-acoustics, a technology based on "light-in and sound-out," with diagnostic ultrasound - (OA/US). The opto-acoustic images provide a unique blood map in and around suspicious breast masses. Cancerous tumors grow relatively quickly and require significant amounts of blood and oxygen, so a network of blood vessels grows around cancerous masses. Imagio OA/US breast imaging system provides real-time images of these networks and a map of relative oxygen-rich or oxygen-depleted blood. Unlike other functional fusion technologies, Imagio uses no x-rays (ionizing radiation) or injectable contrast agents or radio-isotopes to obtain its information, thereby reducing the patient's exposure to any potentially harmful aspects of imaging.

For more information: www.SenoMedical.com

Related Content

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images

A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images. The algorithm, described at the SBI/ACR Breast Imaging Symposium, used “Deep Learning,“ a form of machine learning, which is a type of artificial intelligence. Graphic courtesy of Sarah Eskreis-Winkler, M.D.

Feature | Artificial Intelligence | April 12, 2019 | By Greg Freiherr
The use of smart algorithms has the potential to make healthcare more efficient.
This image depicts ABUS images with QVCAD results

This image depicts ABUS images with QVCAD results.

Feature | Breast Imaging | April 12, 2019
Imaging Technology News spoke with Bob Foley, vice president of sales and marketing of QView Medical, Inc.,
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...